カテゴリ： QYResearch, 世界, 医療/バイオ

サイクリン依存性キナーゼ（CDK）阻害剤の世界市場2023年：経口、静脈注射、その他

■ 英語タイトル：Global Cyclin-Dependent Kinase (CDK) Inhibitors Market Research Report 2023

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA8731）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA8731
■ 発行日：2023年3月
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：89
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[サイクリン依存性キナーゼ（CDK）阻害剤の世界市場2023年：経口、静脈注射、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

本調査資料はサイクリン依存性キナーゼ（CDK）阻害剤のグローバル市場について調査・分析し、世界のサイクリン依存性キナーゼ（CDK）阻害剤市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（経口、静脈注射、その他）、用途別セグメント分析（病院、薬局、その他）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Sanofi、Pfizer Inc.、Eli Lilly and Company、Novartis、Astex Pharmaceuticals、Bristol-Myers Squibb Company、Merck KGaA、AstraZenecaなどが含まれています。サイクリン依存性キナーゼ（CDK）阻害剤のグローバル市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。新型コロナとロシア・ウクライナ戦争の影響は、サイクリン依存性キナーゼ（CDK）阻害剤市場規模を算出する際に考慮しました。

・サイクリン依存性キナーゼ（CDK）阻害剤市場の概要
- 製品の定義
- サイクリン依存性キナーゼ（CDK）阻害剤の種類別セグメント
- 世界のサイクリン依存性キナーゼ（CDK）阻害剤市場規模：タイプ別分析（経口、静脈注射、その他）
- サイクリン依存性キナーゼ（CDK）阻害剤の用途別セグメント
- 世界のサイクリン依存性キナーゼ（CDK）阻害剤市場規模：用途別分析（病院、薬局、その他）
- 世界のサイクリン依存性キナーゼ（CDK）阻害剤市場規模予測（2018年-2029年）
- サイクリン依存性キナーゼ（CDK）阻害剤の平均価格推移（2018年-2029年）
- 前提条件と制限事項

・メーカー別競争状況
- メーカー別市場シェア
- 世界の主要メーカー、業界ランキング分析
- メーカー別平均価格
- サイクリン依存性キナーゼ（CDK）阻害剤市場の競争状況およびトレンド

・サイクリン依存性キナーゼ（CDK）阻害剤の地域別市場規模
- 北米のサイクリン依存性キナーゼ（CDK）阻害剤市場規模（2018年-2029年）
- 米国のサイクリン依存性キナーゼ（CDK）阻害剤市場規模（2018年-2029年）
- ヨーロッパのサイクリン依存性キナーゼ（CDK）阻害剤市場規模（2018年-2029年）
- アジア太平洋のサイクリン依存性キナーゼ（CDK）阻害剤市場規模（2018年-2029年）
- 中国のサイクリン依存性キナーゼ（CDK）阻害剤市場規模（2018年-2029年）
- 日本のサイクリン依存性キナーゼ（CDK）阻害剤市場規模（2018年-2029年）
- 韓国のサイクリン依存性キナーゼ（CDK）阻害剤市場規模（2018年-2029年）
- インドのサイクリン依存性キナーゼ（CDK）阻害剤市場規模（2018年-2029年）
- オーストラリアのサイクリン依存性キナーゼ（CDK）阻害剤市場規模（2018年-2029年）
- 中南米のサイクリン依存性キナーゼ（CDK）阻害剤市場規模（2018年-2029年）
- 中東・アフリカのサイクリン依存性キナーゼ（CDK）阻害剤市場規模（2018年-2029年）

・種類別セグメント：経口、静脈注射、その他
- 世界のサイクリン依存性キナーゼ（CDK）阻害剤のタイプ別販売量（2018年-2023年）
- 世界のサイクリン依存性キナーゼ（CDK）阻害剤のタイプ別売上（2018年-2023年）
- 世界のサイクリン依存性キナーゼ（CDK）阻害剤のタイプ別価格

・用途別セグメント：病院、薬局、その他
- 世界のサイクリン依存性キナーゼ（CDK）阻害剤の用途別販売量（2018年-2023年）
- 世界のサイクリン依存性キナーゼ（CDK）阻害剤の用途別売上（2018年-2023年）
- 世界のサイクリン依存性キナーゼ（CDK）阻害剤の用途別価格

・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向
Sanofi、Pfizer Inc.、Eli Lilly and Company、Novartis、Astex Pharmaceuticals、Bristol-Myers Squibb Company、Merck KGaA、AstraZeneca

・産業チェーンと販売チャネルの分析
- サイクリン依存性キナーゼ（CDK）阻害剤産業チェーン分析
- サイクリン依存性キナーゼ（CDK）阻害剤の主要原材料
- サイクリン依存性キナーゼ（CDK）阻害剤の販売チャネル
- サイクリン依存性キナーゼ（CDK）阻害剤のディストリビューター
- サイクリン依存性キナーゼ（CDK）阻害剤の主要顧客

・サイクリン依存性キナーゼ（CDK）阻害剤市場ダイナミクス
- サイクリン依存性キナーゼ（CDK）阻害剤の業界動向
- サイクリン依存性キナーゼ（CDK）阻害剤市場の成長ドライバ、課題、阻害要因

・調査の結論

・調査手法と情報源

Highlights
The global Cyclin-Dependent Kinase (CDK) Inhibitors market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Cyclin-Dependent Kinase (CDK) Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Cyclin-Dependent Kinase (CDK) Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Cyclin-Dependent Kinase (CDK) Inhibitors include Sanofi, Pfizer Inc., Eli Lilly and Company, Novartis, Astex Pharmaceuticals, Bristol-Myers Squibb Company, Merck KGaA and AstraZeneca, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cyclin-Dependent Kinase (CDK) Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cyclin-Dependent Kinase (CDK) Inhibitors.
The Cyclin-Dependent Kinase (CDK) Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Cyclin-Dependent Kinase (CDK) Inhibitors market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cyclin-Dependent Kinase (CDK) Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Sanofi
Pfizer Inc.
Eli Lilly and Company
Novartis
Astex Pharmaceuticals
Bristol-Myers Squibb Company
Merck KGaA
AstraZeneca
Segment by Type
Oral
Intravenous Injection
Others
Segment by Application
Hospital
Pharmacy
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Cyclin-Dependent Kinase (CDK) Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Cyclin-Dependent Kinase (CDK) Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 Cyclin-Dependent Kinase (CDK) Inhibitors Market Overview
1.1 Product Overview and Scope of Cyclin-Dependent Kinase (CDK) Inhibitors
1.2 Cyclin-Dependent Kinase (CDK) Inhibitors Segment by Type
1.2.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Market Value Comparison by Type (2023-2029)
1.2.2 Oral
1.2.3 Intravenous Injection
1.2.4 Others
1.3 Cyclin-Dependent Kinase (CDK) Inhibitors Segment by Application
1.3.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Others
1.4 Global Cyclin-Dependent Kinase (CDK) Inhibitors Market Size Estimates and Forecasts
1.4.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue 2018-2029
1.4.2 Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales 2018-2029
1.4.3 Global Cyclin-Dependent Kinase (CDK) Inhibitors Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Cyclin-Dependent Kinase (CDK) Inhibitors Market Competition by Manufacturers
2.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales Market Share by Manufacturers (2018-2023)
2.2 Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Cyclin-Dependent Kinase (CDK) Inhibitors Average Price by Manufacturers (2018-2023)
2.4 Global Cyclin-Dependent Kinase (CDK) Inhibitors Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Cyclin-Dependent Kinase (CDK) Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Cyclin-Dependent Kinase (CDK) Inhibitors, Product Type & Application
2.7 Cyclin-Dependent Kinase (CDK) Inhibitors Market Competitive Situation and Trends
2.7.1 Cyclin-Dependent Kinase (CDK) Inhibitors Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Cyclin-Dependent Kinase (CDK) Inhibitors Players Market Share by Revenue
2.7.3 Global Cyclin-Dependent Kinase (CDK) Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Cyclin-Dependent Kinase (CDK) Inhibitors Retrospective Market Scenario by Region
3.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Cyclin-Dependent Kinase (CDK) Inhibitors Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Region: 2018-2029
3.2.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Region: 2018-2023
3.2.2 Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Region: 2024-2029
3.3 Global Cyclin-Dependent Kinase (CDK) Inhibitors Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Region: 2018-2029
3.3.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Region: 2018-2023
3.3.2 Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Region: 2024-2029
3.4 North America Cyclin-Dependent Kinase (CDK) Inhibitors Market Facts & Figures by Country
3.4.1 North America Cyclin-Dependent Kinase (CDK) Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Country (2018-2029)
3.4.3 North America Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Cyclin-Dependent Kinase (CDK) Inhibitors Market Facts & Figures by Country
3.5.1 Europe Cyclin-Dependent Kinase (CDK) Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Country (2018-2029)
3.5.3 Europe Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Cyclin-Dependent Kinase (CDK) Inhibitors Market Facts & Figures by Country
3.6.1 Asia Pacific Cyclin-Dependent Kinase (CDK) Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Country (2018-2029)
3.6.3 Asia Pacific Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Cyclin-Dependent Kinase (CDK) Inhibitors Market Facts & Figures by Country
3.7.1 Latin America Cyclin-Dependent Kinase (CDK) Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Country (2018-2029)
3.7.3 Latin America Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Cyclin-Dependent Kinase (CDK) Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa Cyclin-Dependent Kinase (CDK) Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Country (2018-2029)
3.8.3 Middle East and Africa Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Type (2018-2029)
4.1.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Type (2018-2023)
4.1.2 Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Type (2024-2029)
4.1.3 Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales Market Share by Type (2018-2029)
4.2 Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Type (2018-2029)
4.2.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Type (2018-2023)
4.2.2 Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Type (2024-2029)
4.2.3 Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Market Share by Type (2018-2029)
4.3 Global Cyclin-Dependent Kinase (CDK) Inhibitors Price by Type (2018-2029)
5 Segment by Application
5.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Application (2018-2029)
5.1.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Application (2018-2023)
5.1.2 Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Application (2024-2029)
5.1.3 Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales Market Share by Application (2018-2029)
5.2 Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Application (2018-2029)
5.2.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Application (2018-2023)
5.2.2 Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Application (2024-2029)
5.2.3 Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Market Share by Application (2018-2029)
5.3 Global Cyclin-Dependent Kinase (CDK) Inhibitors Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Sanofi
6.1.1 Sanofi Corporation Information
6.1.2 Sanofi Description and Business Overview
6.1.3 Sanofi Cyclin-Dependent Kinase (CDK) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Sanofi Cyclin-Dependent Kinase (CDK) Inhibitors Product Portfolio
6.1.5 Sanofi Recent Developments/Updates
6.2 Pfizer Inc.
6.2.1 Pfizer Inc. Corporation Information
6.2.2 Pfizer Inc. Description and Business Overview
6.2.3 Pfizer Inc. Cyclin-Dependent Kinase (CDK) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Pfizer Inc. Cyclin-Dependent Kinase (CDK) Inhibitors Product Portfolio
6.2.5 Pfizer Inc. Recent Developments/Updates
6.3 Eli Lilly and Company
6.3.1 Eli Lilly and Company Corporation Information
6.3.2 Eli Lilly and Company Description and Business Overview
6.3.3 Eli Lilly and Company Cyclin-Dependent Kinase (CDK) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Eli Lilly and Company Cyclin-Dependent Kinase (CDK) Inhibitors Product Portfolio
6.3.5 Eli Lilly and Company Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Corporation Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Cyclin-Dependent Kinase (CDK) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Novartis Cyclin-Dependent Kinase (CDK) Inhibitors Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Astex Pharmaceuticals
6.5.1 Astex Pharmaceuticals Corporation Information
6.5.2 Astex Pharmaceuticals Description and Business Overview
6.5.3 Astex Pharmaceuticals Cyclin-Dependent Kinase (CDK) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Astex Pharmaceuticals Cyclin-Dependent Kinase (CDK) Inhibitors Product Portfolio
6.5.5 Astex Pharmaceuticals Recent Developments/Updates
6.6 Bristol-Myers Squibb Company
6.6.1 Bristol-Myers Squibb Company Corporation Information
6.6.2 Bristol-Myers Squibb Company Description and Business Overview
6.6.3 Bristol-Myers Squibb Company Cyclin-Dependent Kinase (CDK) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Bristol-Myers Squibb Company Cyclin-Dependent Kinase (CDK) Inhibitors Product Portfolio
6.6.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.7 Merck KGaA
6.6.1 Merck KGaA Corporation Information
6.6.2 Merck KGaA Description and Business Overview
6.6.3 Merck KGaA Cyclin-Dependent Kinase (CDK) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Merck KGaA Cyclin-Dependent Kinase (CDK) Inhibitors Product Portfolio
6.7.5 Merck KGaA Recent Developments/Updates
6.8 AstraZeneca
6.8.1 AstraZeneca Corporation Information
6.8.2 AstraZeneca Description and Business Overview
6.8.3 AstraZeneca Cyclin-Dependent Kinase (CDK) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.8.4 AstraZeneca Cyclin-Dependent Kinase (CDK) Inhibitors Product Portfolio
6.8.5 AstraZeneca Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Cyclin-Dependent Kinase (CDK) Inhibitors Industry Chain Analysis
7.2 Cyclin-Dependent Kinase (CDK) Inhibitors Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Cyclin-Dependent Kinase (CDK) Inhibitors Production Mode & Process
7.4 Cyclin-Dependent Kinase (CDK) Inhibitors Sales and Marketing
7.4.1 Cyclin-Dependent Kinase (CDK) Inhibitors Sales Channels
7.4.2 Cyclin-Dependent Kinase (CDK) Inhibitors Distributors
7.5 Cyclin-Dependent Kinase (CDK) Inhibitors Customers
8 Cyclin-Dependent Kinase (CDK) Inhibitors Market Dynamics
8.1 Cyclin-Dependent Kinase (CDK) Inhibitors Industry Trends
8.2 Cyclin-Dependent Kinase (CDK) Inhibitors Market Drivers
8.3 Cyclin-Dependent Kinase (CDK) Inhibitors Market Challenges
8.4 Cyclin-Dependent Kinase (CDK) Inhibitors Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Tables
Table 1. Global Cyclin-Dependent Kinase (CDK) Inhibitors Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Cyclin-Dependent Kinase (CDK) Inhibitors Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Cyclin-Dependent Kinase (CDK) Inhibitors Market Competitive Situation by Manufacturers in 2022
Table 4. Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Cyclin-Dependent Kinase (CDK) Inhibitors Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Cyclin-Dependent Kinase (CDK) Inhibitors, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Cyclin-Dependent Kinase (CDK) Inhibitors, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Cyclin-Dependent Kinase (CDK) Inhibitors, Product Type & Application
Table 12. Global Key Manufacturers of Cyclin-Dependent Kinase (CDK) Inhibitors, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Cyclin-Dependent Kinase (CDK) Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cyclin-Dependent Kinase (CDK) Inhibitors as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Cyclin-Dependent Kinase (CDK) Inhibitors Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Region (2018-2023) & (K Units)
Table 18. Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales Market Share by Region (2018-2023)
Table 19. Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Region (2024-2029) & (K Units)
Table 20. Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales Market Share by Region (2024-2029)
Table 21. Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Market Share by Region (2018-2023)
Table 23. Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Market Share by Region (2024-2029)
Table 25. North America Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Country (2018-2023) & (K Units)
Table 27. North America Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Country (2024-2029) & (K Units)
Table 28. North America Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Country (2018-2023) & (K Units)
Table 32. Europe Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Country (2024-2029) & (K Units)
Table 33. Europe Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales (K Units) by Type (2018-2023)
Table 51. Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales (K Units) by Type (2024-2029)
Table 52. Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales Market Share by Type (2018-2023)
Table 53. Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales Market Share by Type (2024-2029)
Table 54. Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Market Share by Type (2018-2023)
Table 57. Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Market Share by Type (2024-2029)
Table 58. Global Cyclin-Dependent Kinase (CDK) Inhibitors Price (US$/Unit) by Type (2018-2023)
Table 59. Global Cyclin-Dependent Kinase (CDK) Inhibitors Price (US$/Unit) by Type (2024-2029)
Table 60. Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales (K Units) by Application (2018-2023)
Table 61. Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales (K Units) by Application (2024-2029)
Table 62. Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales Market Share by Application (2018-2023)
Table 63. Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales Market Share by Application (2024-2029)
Table 64. Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Market Share by Application (2018-2023)
Table 67. Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Market Share by Application (2024-2029)
Table 68. Global Cyclin-Dependent Kinase (CDK) Inhibitors Price (US$/Unit) by Application (2018-2023)
Table 69. Global Cyclin-Dependent Kinase (CDK) Inhibitors Price (US$/Unit) by Application (2024-2029)
Table 70. Sanofi Corporation Information
Table 71. Sanofi Description and Business Overview
Table 72. Sanofi Cyclin-Dependent Kinase (CDK) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. Sanofi Cyclin-Dependent Kinase (CDK) Inhibitors Product
Table 74. Sanofi Recent Developments/Updates
Table 75. Pfizer Inc. Corporation Information
Table 76. Pfizer Inc. Description and Business Overview
Table 77. Pfizer Inc. Cyclin-Dependent Kinase (CDK) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. Pfizer Inc. Cyclin-Dependent Kinase (CDK) Inhibitors Product
Table 79. Pfizer Inc. Recent Developments/Updates
Table 80. Eli Lilly and Company Corporation Information
Table 81. Eli Lilly and Company Description and Business Overview
Table 82. Eli Lilly and Company Cyclin-Dependent Kinase (CDK) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Eli Lilly and Company Cyclin-Dependent Kinase (CDK) Inhibitors Product
Table 84. Eli Lilly and Company Recent Developments/Updates
Table 85. Novartis Corporation Information
Table 86. Novartis Description and Business Overview
Table 87. Novartis Cyclin-Dependent Kinase (CDK) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Novartis Cyclin-Dependent Kinase (CDK) Inhibitors Product
Table 89. Novartis Recent Developments/Updates
Table 90. Astex Pharmaceuticals Corporation Information
Table 91. Astex Pharmaceuticals Description and Business Overview
Table 92. Astex Pharmaceuticals Cyclin-Dependent Kinase (CDK) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Astex Pharmaceuticals Cyclin-Dependent Kinase (CDK) Inhibitors Product
Table 94. Astex Pharmaceuticals Recent Developments/Updates
Table 95. Bristol-Myers Squibb Company Corporation Information
Table 96. Bristol-Myers Squibb Company Description and Business Overview
Table 97. Bristol-Myers Squibb Company Cyclin-Dependent Kinase (CDK) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Bristol-Myers Squibb Company Cyclin-Dependent Kinase (CDK) Inhibitors Product
Table 99. Bristol-Myers Squibb Company Recent Developments/Updates
Table 100. Merck KGaA Corporation Information
Table 101. Merck KGaA Description and Business Overview
Table 102. Merck KGaA Cyclin-Dependent Kinase (CDK) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Merck KGaA Cyclin-Dependent Kinase (CDK) Inhibitors Product
Table 104. Merck KGaA Recent Developments/Updates
Table 105. AstraZeneca Corporation Information
Table 106. AstraZeneca Description and Business Overview
Table 107. AstraZeneca Cyclin-Dependent Kinase (CDK) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. AstraZeneca Cyclin-Dependent Kinase (CDK) Inhibitors Product
Table 109. AstraZeneca Recent Developments/Updates
Table 110. Key Raw Materials Lists
Table 111. Raw Materials Key Suppliers Lists
Table 112. Cyclin-Dependent Kinase (CDK) Inhibitors Distributors List
Table 113. Cyclin-Dependent Kinase (CDK) Inhibitors Customers List
Table 114. Cyclin-Dependent Kinase (CDK) Inhibitors Market Trends
Table 115. Cyclin-Dependent Kinase (CDK) Inhibitors Market Drivers
Table 116. Cyclin-Dependent Kinase (CDK) Inhibitors Market Challenges
Table 117. Cyclin-Dependent Kinase (CDK) Inhibitors Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Cyclin-Dependent Kinase (CDK) Inhibitors
Figure 2. Global Cyclin-Dependent Kinase (CDK) Inhibitors Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Cyclin-Dependent Kinase (CDK) Inhibitors Market Share by Type in 2022 & 2029
Figure 4. Oral Product Picture
Figure 5. Intravenous Injection Product Picture
Figure 6. Others Product Picture
Figure 7. Global Cyclin-Dependent Kinase (CDK) Inhibitors Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 8. Global Cyclin-Dependent Kinase (CDK) Inhibitors Market Share by Application in 2022 & 2029
Figure 9. Hospital
Figure 10. Pharmacy
Figure 11. Others
Figure 12. Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Cyclin-Dependent Kinase (CDK) Inhibitors Market Size (2018-2029) & (US$ Million)
Figure 14. Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales (2018-2029) & (K Units)
Figure 15. Global Cyclin-Dependent Kinase (CDK) Inhibitors Average Price (US$/Unit) & (2018-2029)
Figure 16. Cyclin-Dependent Kinase (CDK) Inhibitors Report Years Considered
Figure 17. Cyclin-Dependent Kinase (CDK) Inhibitors Sales Share by Manufacturers in 2022
Figure 18. Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Share by Manufacturers in 2022
Figure 19. The Global 5 and 10 Largest Cyclin-Dependent Kinase (CDK) Inhibitors Players: Market Share by Revenue in 2022
Figure 20. Cyclin-Dependent Kinase (CDK) Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 21. Global Cyclin-Dependent Kinase (CDK) Inhibitors Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 22. North America Cyclin-Dependent Kinase (CDK) Inhibitors Sales Market Share by Country (2018-2029)
Figure 23. North America Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Market Share by Country (2018-2029)
Figure 24. United States Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Canada Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 26. Europe Cyclin-Dependent Kinase (CDK) Inhibitors Sales Market Share by Country (2018-2029)
Figure 27. Europe Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Market Share by Country (2018-2029)
Figure 28. Germany Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. France Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. U.K. Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Italy Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Russia Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Asia Pacific Cyclin-Dependent Kinase (CDK) Inhibitors Sales Market Share by Region (2018-2029)
Figure 34. Asia Pacific Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Market Share by Region (2018-2029)
Figure 35. China Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Japan Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. South Korea Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. India Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Australia Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. China Taiwan Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Indonesia Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Thailand Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Malaysia Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Latin America Cyclin-Dependent Kinase (CDK) Inhibitors Sales Market Share by Country (2018-2029)
Figure 45. Latin America Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Market Share by Country (2018-2029)
Figure 46. Mexico Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Brazil Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Argentina Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Middle East & Africa Cyclin-Dependent Kinase (CDK) Inhibitors Sales Market Share by Country (2018-2029)
Figure 50. Middle East & Africa Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Market Share by Country (2018-2029)
Figure 51. Turkey Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Saudi Arabia Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. UAE Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Global Sales Market Share of Cyclin-Dependent Kinase (CDK) Inhibitors by Type (2018-2029)
Figure 55. Global Revenue Market Share of Cyclin-Dependent Kinase (CDK) Inhibitors by Type (2018-2029)
Figure 56. Global Cyclin-Dependent Kinase (CDK) Inhibitors Price (US$/Unit) by Type (2018-2029)
Figure 57. Global Sales Market Share of Cyclin-Dependent Kinase (CDK) Inhibitors by Application (2018-2029)
Figure 58. Global Revenue Market Share of Cyclin-Dependent Kinase (CDK) Inhibitors by Application (2018-2029)
Figure 59. Global Cyclin-Dependent Kinase (CDK) Inhibitors Price (US$/Unit) by Application (2018-2029)
Figure 60. Cyclin-Dependent Kinase (CDK) Inhibitors Value Chain
Figure 61. Cyclin-Dependent Kinase (CDK) Inhibitors Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • BCL-2（B細胞リンパ腫2）阻害剤の世界市場2023年～2027年
  • アンピシリン三水和物のグローバル市場展望 2023年-2029年：筋肉注射、静脈注射
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA8731 )"サイクリン依存性キナーゼ（CDK）阻害剤の世界市場2023年：経口、静脈注射、その他" (英文：Global Cyclin-Dependent Kinase (CDK) Inhibitors Market Research Report 2023)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。